ents were $576,307. Revenue for the quarter was $189,741. The company indicated that the decrease is attributable to its license agreement with Pieris Pharmaceuticals and a study agreement with Merck (MRK). The company stated, “As the result of the Company’s determinations in June 2017 to terminate its research and development function and sell its laboratory equipment, as well as to wind down its remaining operations, the Company does not expect to conduct any further activities pursuant to its study agreement with Merck. Consequently, the Company does not expect to recognize any additional revenue with respect ot the Merck agreement.”
ENUM pumpers wet dream LOL
News 
Market Data 
Discover 
